On July 28, 2017, the U.S. Food and Drug Administration approved the atypical antipsychotic Abilify Maintena (aripiprazole) as a maintenance monotherapy treatment for patients with Bipolar I disorder. This approval of the once-monthly intramuscular injectable may be a welcome addition for many patients who would prefer not to take their medication daily. Abilify Maintena should only be used in patients who have successfully taken oral aripiprazole without developing intolerable side effects and oral aripiprazole must be given concomitantly for 14 days after receiving the first Abilify Maintena injection.
Press Release
Member Resources: